Homburger with Sophia Genetics in its Nasdaq Initial Public Offering

Homburger acted as Swiss counsel to Sophia Genetics on the initial listing of its shares on the Nasdaq Stock Market (ticker: SOPH). Sophia Genetics is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research.

The pricing of its initial public offering of 13,000,000 ordinary shares was listed at a price of $18 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated fees and offering expenses payable by Sophia Genetics, are expected to be approximately $234 million. The offering is expected to close on July 27, 2021, subject to customary closing conditions.

The Homburger team advising Sophia Genetics is led by corporate/m&a, capital markets partners Dieter Gericke (pictured top left) and Daniel Häusermann  (pictured top right ) and includes partner Reto Heuberger (tax), associates Estelle Piccard (corporate / m&a, capital markets), Ivan Marijanovic (employment and executive compensation), Gabriel Kasper (data protection) and Philippe Weber (tax) as well as junior associates Alessandra Dumitru and Ferdinand Berthold (both corporate / m&a, capital markets).

J.P. Morgan, Morgan Stanley, Cowen and Credit Suisse are acting as joint book-running managers for the offering.